Clinical Trials Directory

Trials / Completed

CompletedNCT01283958

The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Status
Completed
Phase
Study type
Observational
Enrollment
12 (actual)
Sponsor
Gachon University Gil Medical Center · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Conditions

Timeline

Start date
2007-09-01
Completion
2010-05-01
First posted
2011-01-26
Last updated
2011-01-26

Source: ClinicalTrials.gov record NCT01283958. Inclusion in this directory is not an endorsement.

The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome (NCT01283958) · Clinical Trials Directory